Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial.

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with overweight or obesity and knee osteoarthritis, according to topline results from the TRIUMPH-4 trial.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide,

Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, underscoring the potential of its triple-agonist therapy to reshape treatment for obesity and related metabolic conditions.

Up to 28.7% weight loss in a 68-week late-stage trial * Reduced knee osteoarthritis pain by up to 62.6% * First "triple-hormone" injection targeting GLP-1, GIP, and //glucagon The next-generation obesity drug is here: "Retatrutide".